Browsing Tag
SV-102
2 posts
Syncromune targets broader oncology opportunities with proprietary tumor-directed immunotherapy technology
Syncromune's SYNC-T reports 80% two-year prostate cancer survival as its Phase 2a trial expands. Explore commercial potential and risks.
What the LEGION-100 trial could mean for the future of combination immunotherapy strategies
Can the LEGION-100 trial redefine immunotherapy strategies? Explore what Syncromune Inc.’s approach means for oncology and future cancer treatments.